Abstract
Circulating tumor cell (CTC) enumeration provides prognostic but not predictive information for chemotherapy in metastatic breast cancer. Because CTC measurement is reproducible and allows molecular profiling, an assay to assess endocrine resistance was developed. Whether this CTC-based assay can be used to reliably select endocrine therapy must be tested.
©2015 American Association for Cancer Research.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Breast Neoplasms / genetics*
-
Female
-
Humans
-
Ki-67 Antigen / genetics*
-
Neoplastic Cells, Circulating / pathology*
-
Proto-Oncogene Proteins c-bcl-2 / genetics*
-
Receptor, ErbB-2 / genetics*
-
Receptors, Estrogen / genetics*
Substances
-
Ki-67 Antigen
-
Proto-Oncogene Proteins c-bcl-2
-
Receptors, Estrogen
-
Receptor, ErbB-2